PIVKA-II Cutoff Value for HCC Diagnosis
The optimal cutoff value for PIVKA-II in diagnosing hepatocellular carcinoma varies by clinical context, but the most widely validated threshold is 40 mAU/mL for screening/surveillance purposes, with higher cutoffs (677-1609 mAU/mL) providing better specificity for definitive diagnosis.
Guideline-Based Context
The available guidelines 1 acknowledge PIVKA-II (also called des-gamma-carboxy prothrombin or DGCP) as a serological marker for HCC but notably do not establish specific cutoff values or recommend its routine use for surveillance. The 2005 AASLD/Hepatology guidelines explicitly state that most reports on PIVKA-II have evaluated it in diagnostic mode rather than surveillance, and there is insufficient justification for routine use as a screening marker 1. The guidelines also note that PIVKA-II may be a marker for portal vein invasion, suggesting it identifies late rather than early disease—a critical limitation for screening 1.
The 2012 EASL-EORTC guidelines 2 and subsequent updates 3 focus on imaging-based diagnosis and do not incorporate PIVKA-II into diagnostic algorithms, instead emphasizing the radiological hallmark of arterial hypervascularity with venous/late phase washout.
Research-Derived Cutoff Values
Since guidelines provide limited direction, recent high-quality research fills this gap:
For General HCC Diagnosis:
40 mAU/mL: The most commonly validated threshold across multiple studies 4, 5. A 2021 multi-center Chinese study of 784 subjects demonstrated that 40 mAU/mL yielded satisfactory specificity, with only 4.81% false positives in chronic hepatitis and 12.80% in cirrhosis patients 5.
37.5-45 mAU/mL range: Studies show optimal performance in this range when discriminating HCC from chronic liver disease. The cutoff of 37.5 mAU/mL achieved 91.78% sensitivity and 96.30% specificity for HCC vs. chronic hepatitis B 5, while 45 mAU/mL showed 77.46% sensitivity and 95.12% specificity for HCC vs. cirrhosis 5.
For Higher Specificity (Definitive Diagnosis):
677 mAU/mL: A 2024 Caucasian study identified this cutoff with AUROC of 84.4% for HCC diagnosis 6. This higher threshold reduces false positives in cirrhotic populations.
1609.5 mAU/mL: A 2026 study established this Youden-optimized cutoff for identifying aggressive HCC (beyond Milan criteria or with portal vein thrombosis) in AFP-normal patients, achieving 54% sensitivity but 94% specificity with PPV of 91.9% 7.
For Ultra-High Risk Stratification:
- ≥4000 mAU/mL: This threshold showed 100% positive predictive value for aggressive tumor biology in AFP-normal HCC 7, useful for transplant exclusion decisions.
Clinical Algorithm for PIVKA-II Use
For Surveillance/Screening in High-Risk Patients:
- Use 40 mAU/mL as the initial threshold 4, 5
- Sensitivity: 80.80%, Specificity: 90.43% 4
- This cutoff minimizes false positives while maintaining acceptable sensitivity
For Diagnostic Confirmation:
- In cirrhotic patients with liver nodules, use 677 mAU/mL 6
- Provides better specificity (reduces false positives from cirrhosis-related elevations)
- Particularly valuable when AFP is non-diagnostic (<400 ng/mL)
For Risk Stratification:
- 400 mAU/mL: Sensitivity-oriented cutoff for detecting aggressive disease 7
- 1609.5 mAU/mL: Balanced cutoff for aggressive HCC 7
- ≥4000 mAU/mL: Identifies ultra-high-risk patients 7
Important Caveats
Factors That Elevate PIVKA-II (False Positives):
- Elevated bilirubin and ALT 8
- Decreased albumin 8
- Vitamin K deficiency or warfarin use (by definition of the marker)
- Advanced cirrhosis with synthetic dysfunction
Factors Associated with False Negatives:
- Small tumor size (<3 cm) 8
- Well-differentiated HCC 8
- Absence of vascular invasion 8
- Non-viral etiology 8
Combination Strategy: The combination of PIVKA-II + AFP consistently outperforms either marker alone, with AUROC reaching 0.90 6 to 0.900 8. Use both markers together rather than PIVKA-II alone, particularly in:
- Patients with preserved liver function (normal bilirubin, albumin, RBC) 8
- Small tumors (<3 cm) 8
- AFP-negative HCC (where PIVKA-II shows 73.1% sensitivity) 9
Practical Recommendation
For routine clinical practice, adopt a tiered approach:
- Screening threshold: 40 mAU/mL - triggers further imaging workup 4, 5
- Diagnostic threshold: 677 mAU/mL - supports HCC diagnosis in appropriate clinical context 6
- Always combine with AFP measurement - improves overall diagnostic accuracy 6, 8, 9
- Interpret in context of liver function - elevated bilirubin/low albumin increases false positive risk 8
The "50-50 rule" for treatment monitoring (≥50% reduction indicates response, ≥50% increase indicates progression) has been validated for AFP-negative HCC on systemic therapy 10, providing an additional clinical application beyond initial diagnosis.